New brain cancer drug combo enters human testing
NCT ID NCT05635734
Summary
This early-phase study is testing whether adding an investigational drug called azeliragon to the standard initial treatment (radiation plus temozolomide chemotherapy) is safe for adults newly diagnosed with glioblastoma, an aggressive brain cancer. The main goal is to find a safe dose of azeliragon to take alongside standard care. Researchers will also look for early signs that the combination might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Clínic de Barcelona
Barcelona, Barcelona, 08036, Spain
-
Hospital Universitario 12 de Octubre
Madrid, Madrid, 28041, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, Madrid, 28034, Spain
-
Hospital del Mar
Barcelona, Barcelona, 08003, Spain
Conditions
Explore the condition pages connected to this study.